Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01606566
Other study ID # PCIA202/10
Secondary ID 2011-003751-19
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 2012
Est. completion date January 2016

Study information

Verified date February 2022
Source PCI Biotech AS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Amphinex induced PCI of bleomycin ('PC-A11') with superficial and/or interstitial laser light application in patients with recurrent SCCHN.


Description:

Approximately 650 000 new cases of head and neck cancer are diagnosed worldwide each year (2). Europe alone, it is estimated that there are approximately 143 000 new cases and more than 68 000 deaths each year (3). The vast majority (>90%) of head and neck malignancies are squamous cell carcinomas. Most (60-70%) patients with squamous cell carcinoma of the head and neck (SCCHN) present with loco regionally advanced disease. Standard treatment options for SCCHN include surgery, radiotherapy and chemotherapy. Single-modality treatment with surgery or radiotherapy is generally recommended for the 40% of patients who present stage I or II disease. Each of the two modalities results in similar survival with cure rates ranging between 60% and 90%. For the 60% of the patients who present with locally advanced disease at diagnosis, combined modality therapy is generally recommended. For patients with unresectable disease the current standard treatment is concurrent cisplatin-based chemoradiation. This is also the standard for patients with resectable disease when organ preservation is desired and, as adjuvant treatment, for patients with high-risk pathological findings at surgical resection. Despite such an approach, a substantial percentage of patients (20-30%) develop local and/or regional recurrences and distant metastases. Recurrent disease is often not resectable, and even in resectable cases, some patients decline the surgical procedure due to quality of life considerations. Additionally, in recurrent disease the radiation tolerance of the normal tissues makes re-irradiation technically challenging and frequently more toxic than the initial course. The prognosis of patients with recurrent or metastatic SCCHN is generally poor, with a median survival of 6-9 months. The therapeutic ratio in recurrent SCCHN is narrow. Therefore, there is a large unmet medical need for novel treatments in this patient group, both to lengthen overall survival, and to improve the patients' quality of life.


Recruitment information / eligibility

Status Terminated
Enrollment 26
Est. completion date January 2016
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Study eligibility reviewed and approved by interdisciplinary hospital team. 2. Age minimum 18 years. 3. Histologically or cytological confirmed diagnosis of recurrent or metastatic SCCHN considered unsuitable for surgery and radiotherapy (patients with distant or regional metastatic disease may be eligible if local palliation is needed) 4. Performance status (WHO scale/ECOG) = 1. 5. At least one measurable target lesion at baseline. 6. Local disease including margin (0.5 cm) treatable with superficial and/or interstitial laser light application (for superficial lesions: entire tumour assessable for laser light application/interstitial treatment: insertion of implants feasible) 7. Estimated life expectancy of at least 12 weeks. 8. Written informed consent. Exclusion criteria: Prior Treatment: 1. Local treatment of their SCCHN by surgery within the previous 4 weeks or by radiation within the previous 3 months. 2. Previous treatment with systemic chemotherapy for their SCCHN within the last 4 weeks 3. Previous treatment with Photodynamic Therapy within the last 6 months. 4. Prior treatment with bleomycin. 5. Prior treatment with PC-A11. 6. Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) which did not resolve to = grade 2. Current Treatment: 7. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study. 8. Other concurrent anticancer therapies. 9. Treatment with a medicinal product with known or potential drug-drug interaction with bleomycin or Amphinex. Haematology, coagulation and biochemistry: 10. Inadequate bone marrow function: Absolute Neutrophil Count (ANC): < 1.5 x 109/L, or platelet count <100 x 109/L or haemoglobin < 6 mmol/L. 11. Inadequate liver function, defined as: Serum (total) bilirubin > 2 x the Upper Limit of Normal (ULN) for the institution. Aspartate Amino Transferase (ASAT) or Alanine Amino Transferase (ALAT) > 2.5 x ULN. Alkaline phosphatase levels > 2.5 x ULN. 12. Glomerular filtration rate (GFR) < 30ml/min. 13. Clinical significant electrolyte abnormalities (Potassium, Magnesium, Phosphate that is greater than CTCAE grade 3 for both low and high values) Other: 14. Tumours known or suspected to be eroding into a major blood vessel, e.g. carotid artery (interna and /or communis) in or adjacent to the illumination site (minimum distance between tumour tissue and critical structure should be 0.5 cm). 15. Nasopharyngeal carcinoma. 16. Conditions contraindicated for bleomycin treatment (current lung infection, severely impaired pulmonary function) excluded by lung function test (either formal lung function test for patients able to undertake such assessment, or a suitable opinion by an appropriately trained Respiratory / Anaesthetic Clinical Specialist). 17. Conditions that worsen when exposed to light (including porphyria). 18. Inability to undergo CT or MRI. 19. Pregnancy or lactation (female patients with childbearing potential). Serum pregnancy test to be performed within 7 days prior to study PC-A11 treatment start, or within 14 days followed by a confirmatory urine pregnancy test within 7 days prior to study treatment start. 20. For female patients of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) and male patients who are not surgically sterile or with female partners of childbearing potential: absence of highly effective method of contraception resulting in a low failure rate (i.e. less than 1% per year). These methods of contraception according to the note for guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP/ICH/286/95, modification) include consistent and correct use of hormone containing implants and injectables, combined oral contraceptives, hormone containing intrauterine devices, surgical sterilization, sexual abstinence and vasectomy. Note: Abstinence is only acceptable as true abstinence: when this is in line with the preferred and usual lifestyle of the subject, periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 21. Planned surgery, endoscopic examination or dental treatment in first 30 days after PC-A11 treatment. 22. Co-existing ophthalmic disease likely to require slit-lamp examination within the first 90 days after PC-A11 treatment. 23. Congestive heart failure New York Heart Association (NYHA) Class III and IV. Cardiac arrhythmias (except for atrioventricular block type I, Mobitz type II, and Wenckebach type) signs and symptoms of relevant cardiovascular disease. 24. Known allergy or sensitivity to photosensitisers. 25. Ataxia telangiectasia 26. Concomitant malignant disease, with exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix. 27. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned PC-A11 treatment, affect patient compliance or place the patient at high risk from treatment-related complications.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amphinex induced PCI of bleomycin
Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).

Locations

Country Name City State
France Centre Alexis Vautrin (CAV)-Nancy Université Nancy
France CHU de Nantes Hôtel Dieu Nantes Nantes Cedex 1
Germany Charité Comprehensive Cancer Center Berlin
Germany Universitätsklinikum Essen Essen
Germany Universitätsklinikum Schleswig-Holstein Lübeck Schleswig-Holstein
Germany Ludwig Maximilian University Munich München
Lithuania Institute of Oncology, Vilnius University Vilnius
Netherlands The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital Amsterdam
Poland Szpital Specjalistyczny w Brzozowie Brzozów
United Kingdom University College London Hospital London

Sponsors (1)

Lead Sponsor Collaborator
PCI Biotech AS

Countries where clinical trial is conducted

France,  Germany,  Lithuania,  Netherlands,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation of biomarkers obtained from tumour tissue and blood samples The run-in part and expansion part secondary outcome measure 12 months
Other Evaluation of skin photosensitivity The run-in part and expansion part secondary outcome measure 3 months
Other Evaluation of local tumour responses by volumetric measurements. The run-in part and expansion part secondary outcome measure 12 months
Other Evaluation of fluorescence of tumour tissue The run-in part and expansion part secondary outcome measure Day 4
Other Evaluation of pain Scored by a visual analogue score (VAS) 12 months
Primary Dose-limiting toxicities (DLT) The 'run-in part' primary endpoint 3 months
Primary The proportion of patients with non-progressive local disease at 6 months The expansion part primary endpoint 6 months
Secondary Pharmacokinetics of 'PC-A11' in plasma The run-in part and expansion part secondary endpoint 3 months
Secondary The proportion of patients with non-progressive local disease at 3 months The run-in part and expansion part secondary endpoint 12 months
Secondary Proportion of patients with adverse events The run-in part and expansion part safety endpoint 12 months
Secondary Progression free survival The run-in part and expansion part secondary outcome measure 12 months
Secondary QoL using EORTC Quality of Life Questionnaire (QLQ)-C30 version 3.0 and QLQ-H&N35 The run-in part and expansion part secondary outcome measures 12 months
See also
  Status Clinical Trial Phase
Completed NCT02113878 - Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Phase 1
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Terminated NCT02277184 - Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 1
Completed NCT01080066 - A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) N/A
Completed NCT02585973 - Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC Phase 1
Completed NCT01836029 - Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT03715946 - Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer Phase 2
Active, not recruiting NCT03088059 - Biomarker-based Study in R/M SCCHN Phase 2
Recruiting NCT06003231 - A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Phase 2
Terminated NCT02438995 - Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 1
Completed NCT02242916 - State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study N/A
Recruiting NCT01876693 - A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy N/A
Terminated NCT02655068 - Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer Phase 3
Active, not recruiting NCT03509012 - Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT02296684 - Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT03799744 - Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma Phase 1
Completed NCT03109158 - NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 1/Phase 2
Recruiting NCT03485209 - Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Phase 2
Completed NCT01307267 - A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Phase 1
Terminated NCT02822482 - Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss Phase 1/Phase 2